Hospital
Hennepin Healthcare System, INC
Hennepin Healthcare System, INC was paid $708.86M by Medicaid between Jan 2018 and Dec 2024, across 813 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 15% of everything it billed.
33Billing provider infoHENNEPIN HEALTHCARE SYSTEM, INC
MINNEAPOLIS, MN 55415
MINNEAPOLIS, MN 55415
33aNPI1407897309assigned 06/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$708.86M
24GClaims9,991,272
24DCodes billed813
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Minnesota
Rank by total paid#1 of 36
Median peer was paid$11.46M
This provider vs. median62×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,672,891 | $34.44M | |
| 2019 | 1,634,805 | $97.06M | |
| 2020 | 1,310,457 | $78.91M | |
| 2021 | 1,591,820 | $99.20M | |
| 2022 | 1,380,854 | $131.71M | |
| 2023 | 1,352,090 | $146.96M | |
| 2024incomplete | 1,048,355 | $120.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 15% | 1,139,423 | 963,643 | $105.05M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 11% | 118,666 | 90,596 | $78.06M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 9.6% | 94,266 | 82,551 | $67.71M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.5% | 262,223 | 224,415 | $53.35M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.0% | 202,775 | 169,882 | $49.63M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.6% | 460,726 | 395,864 | $32.68M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.6% | 190,002 | 166,029 | $32.39M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.1% | 298,027 | 266,842 | $14.61M |
| A0425 | Ground mileage, per statute mile | 2.0% | 218,688 | 165,992 | $13.99M |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 1.9% | 261,070 | 61,757 | $13.54M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.9% | 69,483 | 32,817 | $13.50M |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 1.8% | 807,067 | 34,044 | $12.98M |
801 more codes
| 99233 | Hospital visit by a doctor, follow-up day (complex) | 1.4% | 145,923 | $10.09M |
| 99215 | Doctor's office visit, returning patient (complex) | 1.3% | 92,877 | $9.18M |
| 90870 | 1.0% | 34,052 | $7.12M | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 2,618 | $4.80M |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 228,242 | $4.69M |
| 36415 | Collection of venous blood by venipuncture | <1% | 355,455 | $4.62M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 59,602 | $4.31M |
| 99223 | Prolong inpt eval add15 m | <1% | 36,910 | $4.24M |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | <1% | 77,248 | $3.39M |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 38,999 | $3.31M |
| J2357 | Injection, omalizumab, 5 mg | <1% | 3,955 | $3.27M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 38,139 | $3.24M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 38,879 | $3.18M |
| 93308 | <1% | 58,413 | $2.84M | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 61,333 | $2.80M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 29,989 | $2.65M |
| A0433 | Advanced life support, level 2 (als 2) | <1% | 2,291 | $2.62M |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 32,866 | $2.54M |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 24,236 | $2.42M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 112,437 | $2.26M |
| G0378 | Hospital observation service, per hour | <1% | 15,731 | $2.26M |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 27,595 | $2.24M |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 36,238 | $2.10M |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 44,281 | $1.99M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 30,694 | $1.96M |
| 90837 | Psychotherapy session, about an hour | <1% | 16,313 | $1.92M |
| 99254 | <1% | 13,768 | $1.91M | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 39,751 | $1.89M |
| 96127 | <1% | 91,624 | $1.87M | |
| 99220 | <1% | 16,723 | $1.86M | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 39,479 | $1.84M |
| 00104 | <1% | 29,398 | $1.75M | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 61,493 | $1.66M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 23,330 | $1.64M |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 52,509 | $1.63M |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 27,624 | $1.58M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 106,375 | $1.57M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 19,633 | $1.47M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,426 | $1.46M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 20,438 | $1.41M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 30,855 | $1.40M |
| X5622 | <1% | 33,241 | $1.36M | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 27,169 | $1.35M |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 18,908 | $1.28M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 29,533 | $1.27M |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 181,798 | $1.24M |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 92,809 | $1.22M |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 21,289 | $1.21M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,503 | $1.19M |
| S0281 | Medical home program, comprehensive care coordination and planning, maintenance of plan | <1% | 36,067 | $1.15M |
| 90961 | <1% | 10,340 | $1.14M | |
| 20610 | <1% | 13,841 | $1.14M | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 146,254 | $1.14M |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 10,689 | $1.13M |
| H2012 | Behavioral health day treatment, per hour | <1% | 22,614 | $1.11M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 8,712 | $1.09M |
| 99217 | <1% | 22,721 | $1.05M | |
| 59410 | <1% | 1,485 | $1.04M | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 17,853 | $1.03M |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 12,404 | $1.03M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 44,756 | $1.03M |
| D1206 | Topical application of fluoride varnish | <1% | 27,542 | $1.01M |
| 90791 | Psychiatric diagnostic evaluation | <1% | 10,694 | $977K |
| 99253 | <1% | 11,294 | $955K | |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 146 | $949K |
| 99255 | <1% | 6,541 | $927K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 11,575 | $927K |
| 76604 | <1% | 23,143 | $882K | |
| 92015 | Determination of refractive state | <1% | 31,255 | $846K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 34,966 | $839K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 25,499 | $833K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,822 | $828K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 4,093 | $828K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 6,168 | $816K |
| 99310 | Prolong nursin fac eval 15m | <1% | 10,567 | $783K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 6,258 | $778K |
| 99443 | <1% | 14,933 | $757K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 5,155 | $751K |
| D1110 | Prophylaxis - adult | <1% | 12,076 | $732K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 5,780 | $716K |
| 99607 | <1% | 23,003 | $704K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 9,461 | $670K |
| D0140 | Limited oral evaluation - problem focused | <1% | 22,223 | $664K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 31,842 | $658K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 9,471 | $657K |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 9,421 | $655K |
| 62323 | <1% | 1,820 | $652K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 25,995 | $642K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,820 | $642K |
| Q3014 | Telehealth originating site facility fee | <1% | 29,703 | $632K |
| 71045 | Radiologic examination, chest; single view | <1% | 84,483 | $626K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,184 | $622K |
| 99460 | <1% | 6,069 | $612K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 5,219 | $601K |
| 97810 | <1% | 20,740 | $600K | |
| D1120 | Dental cleaning, child | <1% | 12,924 | $598K |
| D0120 | Dental checkup, returning patient | <1% | 18,018 | $584K |
| 99221 | <1% | 12,996 | $583K | |
| 95117 | <1% | 17,528 | $563K | |
| 88307 | <1% | 4,854 | $559K | |
| 59025 | Fetal non-stress test | <1% | 10,900 | $553K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 51,621 | $550K |
| 99243 | <1% | 8,545 | $546K | |
| 99219 | <1% | 5,911 | $541K | |
| 16020 | <1% | 5,400 | $539K | |
| 82947 | <1% | 92,344 | $521K | |
| 80051 | <1% | 89,698 | $515K | |
| 82330 | <1% | 89,962 | $495K | |
| 97811 | <1% | 20,030 | $485K | |
| 99205 | Prolong outpt/office vis | <1% | 4,260 | $483K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12,339 | $483K |
| 92551 | <1% | 42,400 | $482K | |
| 87536 | <1% | 14,069 | $477K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 27,017 | $433K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,943 | $425K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12,681 | $415K |
| 80053 | Comprehensive metabolic panel | <1% | 27,784 | $411K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 6,042 | $408K |
| 99480 | Subsequent intensive care, per day, low birth weight infant | <1% | 2,153 | $400K |
| 70496 | <1% | 4,595 | $392K | |
| 36592 | <1% | 14,577 | $391K | |
| 80076 | <1% | 39,652 | $387K | |
| 76801 | <1% | 7,654 | $383K | |
| 99442 | <1% | 10,661 | $375K | |
| 99152 | <1% | 22,155 | $372K | |
| 95811 | <1% | 766 | $370K | |
| 81001 | <1% | 43,852 | $368K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,387 | $368K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 8,537 | $367K |
| 99606 | <1% | 14,915 | $364K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 633 | $362K |
| 92587 | <1% | 2,894 | $361K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 14,963 | $345K |
| 99245 | <1% | 2,949 | $342K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 1,351 | $334K |
| 73630 | <1% | 22,776 | $333K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 778 | $333K |
| D0272 | Bitewings - two radiographic images | <1% | 8,159 | $330K |
| 86592 | <1% | 27,345 | $330K | |
| D0330 | Panoramic radiographic image | <1% | 6,521 | $330K |
| 70498 | <1% | 3,857 | $329K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 4,790 | $323K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 5,625 | $323K |
| 71250 | <1% | 6,324 | $322K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,164 | $322K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 11,039 | $312K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 12,091 | $312K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 4,651 | $307K |
| 90686 | <1% | 46,419 | $306K | |
| 72131 | <1% | 6,124 | $301K | |
| D7240 | Removal of impacted tooth - completely bony | <1% | 1,103 | $298K |
| 82565 | <1% | 92,314 | $293K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 7,185 | $289K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 516 | $287K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 38,317 | $285K |
| 0002A | <1% | 10,427 | $280K | |
| D0274 | Bitewings - four radiographic images | <1% | 5,779 | $280K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 7,684 | $275K |
| 31500 | <1% | 3,299 | $275K | |
| 80061 | Lipid panel | <1% | 15,383 | $264K |
| 31575 | <1% | 4,010 | $262K | |
| D1351 | Sealant - per tooth | <1% | 8,093 | $260K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 7,378 | $260K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,555 | $257K |
| 36591 | <1% | 7,502 | $257K | |
| 99292 | <1% | 2,449 | $255K | |
| 43235 | <1% | 1,566 | $254K | |
| T2022 | Case management, per month | <1% | 1,102 | $253K |
| 72128 | <1% | 4,759 | $249K | |
| 76830 | Ultrasound, transvaginal | <1% | 6,501 | $249K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 3,265 | $249K |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 1,624 | $245K |
| 86481 | <1% | 2,869 | $244K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,436 | $242K |
| 92557 | <1% | 2,799 | $240K | |
| 85027 | <1% | 25,564 | $240K | |
| V2020 | Frames, purchases | <1% | 3,704 | $239K |
| 99479 | Subsequent intensive care, per day, very low birth weight infant | <1% | 1,206 | $235K |
| 0001A | <1% | 10,665 | $235K | |
| 99188 | <1% | 21,227 | $227K | |
| 98940 | <1% | 19,358 | $225K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,565 | $209K |
| V2784 | Lens, polycarbonate or equal, any index, per lens | <1% | 2,816 | $207K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,539 | $207K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 9,060 | $206K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,459 | $205K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,551 | $202K |
| 99605 | <1% | 5,044 | $198K | |
| 91320 | <1% | 2,421 | $198K | |
| 97803 | <1% | 4,566 | $196K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,672 | $190K |
| 93976 | <1% | 4,290 | $190K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 2,877 | $189K |
| 77336 | <1% | 1,603 | $189K | |
| 36416 | <1% | 14,457 | $187K | |
| 88342 | <1% | 5,140 | $182K | |
| D1354 | <1% | 6,565 | $182K | |
| 96900 | <1% | 5,507 | $181K | |
| S0280 | Medical home program, comprehensive care coordination and planning, initial plan | <1% | 1,943 | $178K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,431 | $178K |
| 93296 | <1% | 3,953 | $177K | |
| 59515 | <1% | 215 | $173K | |
| 99252 | <1% | 3,123 | $172K | |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 1,087 | $170K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 19,146 | $169K |
| 92060 | <1% | 4,088 | $169K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 12,830 | $165K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,461 | $164K |
| 84484 | <1% | 27,021 | $158K | |
| D0240 | <1% | 4,018 | $158K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,360 | $158K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,194 | $158K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,916 | $157K |
| 92567 | <1% | 6,865 | $153K | |
| 80502 | <1% | 2,868 | $152K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 75 | $150K |
| 64400 | <1% | 2,348 | $147K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 5,309 | $146K |
| 99183 | <1% | 1,182 | $144K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,429 | $143K |
| 01961 | <1% | 570 | $143K | |
| 76775 | <1% | 6,964 | $141K | |
| Q9991 | Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg | <1% | 62 | $137K |
| 93970 | <1% | 5,168 | $135K | |
| 77427 | <1% | 606 | $134K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 694 | $133K |
| 73610 | <1% | 14,402 | $133K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,775 | $132K |
| 73030 | <1% | 11,245 | $131K | |
| 74018 | <1% | 16,837 | $122K | |
| 29581 | <1% | 1,163 | $122K | |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | <1% | 56 | $121K |
| 82948 | <1% | 27,136 | $121K | |
| 93971 | <1% | 7,477 | $118K | |
| 64615 | <1% | 617 | $118K | |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 6,058 | $118K |
| 95024 | <1% | 577 | $118K | |
| 00840 | <1% | 402 | $116K | |
| 99173 | <1% | 46,475 | $115K | |
| 92341 | <1% | 5,809 | $110K | |
| 90677 | <1% | 2,082 | $103K | |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 1,829 | $100K |
| 96132 | <1% | 898 | $99K | |
| 46600 | <1% | 1,705 | $99K | |
| 90662 | <1% | 2,999 | $99K | |
| 70486 | <1% | 2,295 | $98K | |
| 17110 | <1% | 1,439 | $96K | |
| D2330 | <1% | 1,570 | $96K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15,611 | $96K |
| 85610 | <1% | 16,110 | $96K | |
| 96139 | <1% | 807 | $96K | |
| 95886 | <1% | 1,764 | $95K | |
| 76813 | <1% | 1,051 | $95K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 18,959 | $93K |
| 86803 | <1% | 4,509 | $90K | |
| J3490 | Unclassified drugs | <1% | 20,097 | $89K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,275 | $89K |
| 73562 | <1% | 7,105 | $88K | |
| 84439 | <1% | 4,092 | $87K | |
| 93458 | <1% | 126 | $87K | |
| 73130 | <1% | 10,106 | $86K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,069 | $86K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 810 | $84K |
| 90670 | <1% | 5,942 | $83K | |
| 90962 | <1% | 2,058 | $82K | |
| 99462 | <1% | 2,076 | $82K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,960 | $81K |
| 91200 | <1% | 1,124 | $80K | |
| 90480 | <1% | 4,701 | $80K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 5,630 | $80K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 17,069 | $80K |
| V2203 | Spherocylinder, bifocal, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 1,143 | $80K |
| 97162 | <1% | 2,554 | $79K | |
| 99218 | <1% | 1,182 | $79K | |
| 94375 | <1% | 2,006 | $78K | |
| 77334 | <1% | 329 | $78K | |
| 96133 | <1% | 720 | $78K | |
| 77080 | <1% | 1,821 | $77K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,578 | $76K |
| 87088 | <1% | 6,571 | $75K | |
| 00400 | <1% | 546 | $73K | |
| 99417 | Prolong home eval add 15m | <1% | 1,753 | $71K |
| 97602 | <1% | 957 | $71K | |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | <1% | 4,323 | $69K |
| 72100 | <1% | 6,329 | $69K | |
| 86360 | <1% | 4,783 | $68K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 228 | $66K |
| 0124A | <1% | 2,433 | $65K | |
| 90785 | <1% | 7,972 | $65K | |
| 86682 | <1% | 2,305 | $65K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 19,145 | $64K |
| 36620 | <1% | 2,323 | $64K | |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 1,705 | $64K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 20,978 | $64K |
| 99242 | <1% | 1,633 | $64K | |
| 99402 | <1% | 1,233 | $63K | |
| 87209 | <1% | 2,530 | $63K | |
| 99236 | Prolong inpt eval add15 m | <1% | 453 | $62K |
| D2150 | Silver amalgam - two surfaces, primary or permanent | <1% | 784 | $62K |
| T1016 | Case management, each 15 minutes | <1% | 2,361 | $62K |
| 73502 | <1% | 4,565 | $61K | |
| 86359 | <1% | 4,762 | $61K | |
| 94060 | <1% | 955 | $61K | |
| 00790 | <1% | 313 | $60K | |
| D2331 | <1% | 812 | $60K | |
| 59426 | <1% | 264 | $59K | |
| 36556 | <1% | 975 | $59K | |
| 70491 | <1% | 1,074 | $58K | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 14 | $58K |
| 87340 | <1% | 4,469 | $57K | |
| 83020 | <1% | 3,174 | $57K | |
| 0054A | <1% | 1,802 | $57K | |
| 83655 | <1% | 2,495 | $56K | |
| 72141 | <1% | 721 | $56K | |
| 82728 | <1% | 4,765 | $55K | |
| 99441 | <1% | 3,017 | $55K | |
| 96118 | <1% | 572 | $54K | |
| V5266 | Battery for use in hearing device | <1% | 1,867 | $53K |
| 52000 | <1% | 234 | $52K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,660 | $52K |
| V2103 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 948 | $52K |
| 90691 | <1% | 1,453 | $51K | |
| 76641 | <1% | 1,418 | $51K | |
| 01480 | <1% | 256 | $50K | |
| 73110 | <1% | 6,021 | $50K | |
| 96130 | <1% | 456 | $50K | |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 3,064 | $50K |
| J2704 | Injection, propofol, 10 mg | <1% | 13,287 | $49K |
| 93295 | <1% | 755 | $49K | |
| 0072A | <1% | 1,207 | $49K | |
| 86706 | <1% | 3,772 | $49K | |
| D2140 | <1% | 728 | $48K | |
| 0004A | <1% | 1,745 | $48K | |
| 87177 | <1% | 2,571 | $48K | |
| 99226 | <1% | 505 | $48K | |
| 77066 | Tomosynthesis, mammo | <1% | 775 | $47K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,276 | $46K |
| 92553 | <1% | 560 | $46K | |
| 73564 | <1% | 4,549 | $46K | |
| 99464 | <1% | 837 | $46K | |
| 69210 | <1% | 1,568 | $45K | |
| 95924 | <1% | 225 | $45K | |
| 84153 | <1% | 1,047 | $45K | |
| 71271 | <1% | 930 | $45K | |
| 95720 | <1% | 298 | $45K | |
| 84165 | <1% | 2,862 | $45K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 5,876 | $43K |
| 92083 | <1% | 1,653 | $42K | |
| 99385 | <1% | 730 | $42K | |
| 59425 | <1% | 255 | $42K | |
| 83605 | <1% | 8,111 | $41K | |
| 11900 | <1% | 369 | $41K | |
| 92579 | <1% | 307 | $40K | |
| 92588 | <1% | 287 | $39K | |
| 96116 | <1% | 223 | $39K | |
| A0998 | Ambulance response and treatment, no transport | <1% | 151 | $39K |
| 88341 | <1% | 476 | $39K | |
| 87210 | <1% | 6,651 | $39K | |
| 86704 | <1% | 2,954 | $39K | |
| 88304 | <1% | 2,991 | $38K | |
| 20553 | <1% | 645 | $38K | |
| 76642 | <1% | 627 | $37K | |
| 92370 | <1% | 1,411 | $37K | |
| 51798 | <1% | 1,712 | $37K | |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 82 | $37K |
| 97802 | <1% | 601 | $37K | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 516 | $37K |
| 74183 | <1% | 238 | $36K | |
| 86787 | <1% | 2,630 | $36K | |
| 96158 | <1% | 718 | $36K | |
| 93294 | <1% | 1,535 | $36K | |
| 99397 | <1% | 639 | $36K | |
| 81025 | <1% | 8,541 | $35K | |
| 49083 | <1% | 152 | $35K | |
| 96138 | <1% | 1,001 | $35K | |
| 82043 | <1% | 3,526 | $34K | |
| 97163 | <1% | 495 | $34K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 15,209 | $34K |
| D7230 | <1% | 153 | $33K | |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | <1% | 940 | $33K |
| 0071A | <1% | 872 | $33K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,837 | $33K |
| 80504 | <1% | 856 | $32K | |
| 90750 | <1% | 452 | $32K | |
| 74230 | <1% | 1,035 | $31K | |
| 87077 | <1% | 2,758 | $31K | |
| 73590 | <1% | 4,203 | $30K | |
| 83690 | <1% | 5,196 | $30K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 22 | $30K |
| 76882 | <1% | 1,624 | $30K | |
| 76536 | <1% | 1,051 | $30K | |
| 11981 | <1% | 585 | $29K | |
| 54150 | <1% | 384 | $29K | |
| 99383 | <1% | 554 | $29K | |
| 99451 | <1% | 1,057 | $29K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,387 | $29K |
| 97116 | <1% | 1,231 | $28K | |
| 72170 | <1% | 4,061 | $28K | |
| 99384 | <1% | 375 | $28K | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 536 | $27K |
| 72040 | <1% | 2,043 | $27K | |
| 99140 | <1% | 3,398 | $27K | |
| 83540 | <1% | 3,843 | $25K | |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 1,782 | $25K |
| 92134 | <1% | 1,451 | $25K | |
| 77014 | <1% | 781 | $25K | |
| 78816 | <1% | 84 | $25K | |
| 96040 | <1% | 574 | $24K | |
| 20611 | <1% | 203 | $23K | |
| 99401 | <1% | 657 | $23K | |
| G0008 | Administration of influenza virus vaccine | <1% | 4,275 | $23K |
| 86790 | <1% | 1,462 | $23K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 14,613 | $22K |
| 31231 | <1% | 286 | $22K | |
| V5299 | Hearing service, miscellaneous | <1% | 2,360 | $22K |
| 96156 | <1% | 394 | $22K | |
| 84460 | <1% | 3,150 | $21K | |
| 82570 | <1% | 4,600 | $21K | |
| 99225 | <1% | 461 | $21K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,282 | $21K |
| 97130 | <1% | 321 | $21K | |
| 90474 | <1% | 2,887 | $21K | |
| 99356 | <1% | 286 | $21K | |
| 0052A | <1% | 488 | $21K | |
| 84466 | <1% | 3,605 | $21K | |
| 95800 | <1% | 150 | $20K | |
| 94664 | <1% | 228 | $20K | |
| 77002 | <1% | 605 | $20K | |
| 95923 | <1% | 243 | $19K | |
| 73560 | <1% | 2,812 | $19K | |
| 90656 | <1% | 3,296 | $18K | |
| 82803 | <1% | 2,238 | $18K | |
| 73221 | <1% | 150 | $18K | |
| 81003 | <1% | 4,911 | $18K | |
| 83735 | <1% | 6,491 | $18K | |
| 77263 | <1% | 113 | $18K | |
| 87517 | <1% | 427 | $18K | |
| D5110 | <1% | 25 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,765 | $17K |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 1,268 | $16K |
| 86708 | <1% | 905 | $16K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 583 | $16K |
| 99406 | <1% | 2,577 | $16K | |
| 92552 | <1% | 259 | $16K | |
| 52332 | <1% | 24 | $15K | |
| 86593 | <1% | 493 | $15K | |
| 96119 | <1% | 584 | $15K | |
| 93793 | <1% | 2,166 | $15K | |
| 82607 | <1% | 1,559 | $15K | |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 473 | $15K |
| 80069 | <1% | 1,662 | $15K | |
| 90717 | <1% | 360 | $15K | |
| 96101 | <1% | 433 | $15K | |
| 99201 | <1% | 901 | $15K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 508 | $15K |
| 80503 | <1% | 693 | $14K | |
| 73700 | <1% | 218 | $14K | |
| 80050 | General health panel | <1% | 173 | $14K |
| S9446 | Patient education, not otherwise classified, non-physician provider, group, per session | <1% | 651 | $14K |
| 84703 | <1% | 5,367 | $14K | |
| 58300 | <1% | 397 | $14K | |
| 85018 | <1% | 3,327 | $14K | |
| G0249 | Provision of test materials and equipment for home inr monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; includes: provision of materials for use in the home and reporting of test results to physician; testing not occurring more frequently than once a week; testing materials, billing units of service include 4 tests | <1% | 200 | $14K |
| 74420 | <1% | 209 | $14K | |
| 77300 | <1% | 62 | $13K | |
| 86003 | <1% | 91 | $13K | |
| 90715 | <1% | 910 | $13K | |
| 99316 | <1% | 274 | $13K | |
| 86900 | <1% | 594 | $13K | |
| 73080 | <1% | 1,817 | $12K | |
| 86141 | <1% | 1,816 | $12K | |
| 52310 | <1% | 21 | $12K | |
| 93351 | <1% | 371 | $12K | |
| 92133 | <1% | 488 | $12K | |
| 90651 | <1% | 606 | $12K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 888 | $12K |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 13 | $11K |
| 95910 | <1% | 65 | $11K | |
| G0141 | Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician | <1% | 343 | $11K |
| 76937 | <1% | 1,142 | $11K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 58 | $11K |
| 0012A | <1% | 435 | $11K | |
| 10061 | <1% | 182 | $11K | |
| H1002 | Prenatal care, at risk enhanced service; care coordination | <1% | 504 | $11K |
| V5261 | Hearing aid, digital, binaural, bte | <1% | 14 | $11K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 939 | $10K |
| 93298 | <1% | 382 | $10K | |
| 88112 | <1% | 312 | $10K | |
| 0051A | <1% | 241 | $9K | |
| 97129 | <1% | 338 | $9K | |
| 00142 | <1% | 198 | $9K | |
| 99100 | <1% | 2,580 | $9K | |
| 94010 | <1% | 189 | $9K | |
| 99382 | <1% | 106 | $8K | |
| C9399 | Unclassified drugs or biologicals | <1% | 159 | $8K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 328 | $8K |
| 99306 | Prolong nursin fac eval 15m | <1% | 74 | $8K |
| 95885 | <1% | 91 | $8K | |
| 62321 | <1% | 23 | $8K | |
| 87186 | <1% | 1,660 | $8K | |
| 73552 | <1% | 1,020 | $8K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,366 | $8K |
| 77412 | <1% | 120 | $8K | |
| 86480 | <1% | 182 | $8K | |
| 83880 | <1% | 1,113 | $8K | |
| 78813 | <1% | 28 | $8K | |
| 92586 | <1% | 48 | $8K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 287 | $8K |
| V5267 | Hearing aid or assistive listening device/supplies/accessories, not otherwise specified | <1% | 1,127 | $8K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,604 | $7K |
| 0011A | <1% | 545 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 258 | $7K |
| 80197 | <1% | 1,372 | $7K | |
| 93248 | <1% | 363 | $7K | |
| 84403 | <1% | 344 | $7K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 304 | $7K |
| 0082A | <1% | 187 | $7K | |
| 77065 | Tomosynthesis, mammo | <1% | 132 | $7K |
| 83721 | <1% | 1,166 | $7K | |
| 86780 | <1% | 433 | $7K | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 177 | $7K |
| 87081 | <1% | 3,084 | $7K | |
| 97165 | <1% | 219 | $7K | |
| 76870 | <1% | 304 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,051 | $6K |
| 83970 | <1% | 470 | $6K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 784 | $6K |
| 74019 | <1% | 736 | $6K | |
| 0003A | <1% | 256 | $6K | |
| 90734 | <1% | 254 | $6K | |
| 96376 | <1% | 85 | $6K | |
| 73090 | <1% | 886 | $6K | |
| 99447 | <1% | 226 | $6K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 188 | $6K |
| 90966 | <1% | 66 | $6K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 346 | $6K |
| D1330 | <1% | 835 | $6K | |
| 86762 | <1% | 466 | $6K | |
| 86334 | <1% | 273 | $5K | |
| 99407 | <1% | 170 | $5K | |
| 0031A | <1% | 156 | $5K | |
| D2393 | Resin-based composite - three surfaces, posterior, primary or permanent | <1% | 59 | $5K |
| 94726 | <1% | 397 | $5K | |
| 91300 | <1% | 2,502 | $5K | |
| 82105 | <1% | 588 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,146 | $5K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,335 | $5K |
| 90619 | <1% | 91 | $5K | |
| 88312 | <1% | 105 | $5K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 120 | $5K |
| 99381 | <1% | 107 | $5K | |
| 29580 | <1% | 127 | $5K | |
| 73140 | <1% | 984 | $5K | |
| 86850 | <1% | 594 | $5K | |
| 84450 | <1% | 679 | $5K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,817 | $5K |
| 10005 | <1% | 21 | $5K | |
| 95012 | <1% | 336 | $4K | |
| 86355 | <1% | 74 | $4K | |
| D9420 | <1% | 286 | $4K | |
| 86357 | <1% | 74 | $4K | |
| 90473 | <1% | 288 | $4K | |
| 99403 | <1% | 75 | $4K | |
| 92582 | <1% | 69 | $4K | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 497 | $4K |
| V2207 | Spherocylinder, bifocal, plus or minus 4.25 to plus or minus 7.00d sphere,.12 to 2.00d cylinder, per lens | <1% | 33 | $4K |
| D9222 | <1% | 14 | $4K | |
| 82670 | <1% | 251 | $4K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 202 | $4K |
| C1769 | Guide wire | <1% | 337 | $4K |
| J1815 | Injection, insulin, per 5 units | <1% | 898 | $4K |
| V5160 | Dispensing fee, binaural | <1% | 27 | $4K |
| 86079 | <1% | 57 | $4K | |
| D2332 | <1% | 34 | $4K | |
| 76818 | <1% | 93 | $4K | |
| 10060 | <1% | 50 | $4K | |
| 87149 | <1% | 725 | $4K | |
| 12001 | <1% | 113 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 163 | $4K |
| 84100 | <1% | 3,005 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,634 | $3K |
| 99386 | <1% | 50 | $3K | |
| 93352 | <1% | 126 | $3K | |
| 96417 | <1% | 34 | $3K | |
| 97813 | <1% | 112 | $3K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 39 | $3K |
| 94729 | <1% | 450 | $3K | |
| 77049 | <1% | 29 | $3K | |
| 20552 | <1% | 27 | $3K | |
| 92504 | <1% | 428 | $3K | |
| 85652 | <1% | 1,327 | $3K | |
| 12002 | <1% | 61 | $3K | |
| 86901 | <1% | 596 | $3K | |
| 93280 | <1% | 85 | $3K | |
| 97597 | <1% | 62 | $3K | |
| 93926 | <1% | 121 | $3K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 25 | $3K |
| D2335 | <1% | 33 | $3K | |
| 96415 | <1% | 35 | $3K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 130 | $3K |
| 90672 | <1% | 449 | $3K | |
| 0154A | <1% | 73 | $3K | |
| 97814 | <1% | 110 | $3K | |
| 58301 | <1% | 65 | $3K | |
| 99499 | <1% | 41 | $3K | |
| 80349 | <1% | 44 | $3K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 43 | $3K |
| 12011 | <1% | 91 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,787 | $3K |
| G9002 | Coordinated care fee, maintenance rate | <1% | 186 | $3K |
| D7111 | <1% | 31 | $3K | |
| 0081A | <1% | 77 | $3K | |
| V2107 | Spherocylinder, single vision, plus or minus 4.25 to plus or minus 7.00 sphere, .12 to 2.00d cylinder, per lens | <1% | 27 | $3K |
| 88350 | <1% | 13 | $3K | |
| 93282 | <1% | 45 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 12 | $2K |
| 11982 | <1% | 53 | $2K | |
| 75716 | <1% | 29 | $2K | |
| 96159 | <1% | 129 | $2K | |
| 72146 | <1% | 14 | $2K | |
| 90723 | <1% | 4,138 | $2K | |
| 92002 | <1% | 154 | $2K | |
| 11102 | <1% | 25 | $2K | |
| 74174 | <1% | 13 | $2K | |
| 76942 | <1% | 171 | $2K | |
| 99347 | <1% | 49 | $2K | |
| 92136 | <1% | 71 | $2K | |
| 72070 | <1% | 181 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,029 | $2K |
| D4355 | <1% | 39 | $2K | |
| 99421 | <1% | 1,023 | $2K | |
| 70544 | <1% | 40 | $2K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 58 | $2K |
| 62270 | <1% | 47 | $2K | |
| 85730 | <1% | 460 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,197 | $2K |
| 76770 | <1% | 82 | $2K | |
| 88291 | <1% | 42 | $2K | |
| 90746 | <1% | 51 | $2K | |
| 99305 | <1% | 13 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 707 | $2K |
| 99235 | <1% | 14 | $2K | |
| 87799 | <1% | 215 | $1K | |
| 90970 | <1% | 318 | $1K | |
| 99349 | <1% | 14 | $1K | |
| 88108 | <1% | 61 | $1K | |
| 93299 | <1% | 41 | $1K | |
| 51741 | <1% | 136 | $1K | |
| 82533 | <1% | 94 | $1K | |
| 87070 | <1% | 109 | $1K | |
| 82950 | <1% | 262 | $1K | |
| 85384 | <1% | 169 | $1K | |
| 76820 | <1% | 159 | $1K | |
| H1000 | Prenatal care, at-risk assessment | <1% | 2,410 | $1K |
| 86769 | <1% | 36 | $1K | |
| D2160 | <1% | 14 | $1K | |
| 98968 | <1% | 395 | $1K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 66 | $1K |
| 73060 | <1% | 172 | $1K | |
| 88302 | <1% | 79 | $1K | |
| 95874 | <1% | 44 | $1K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 47 | $1K |
| 99336 | <1% | 22 | $1K | |
| 91301 | <1% | 239 | $1K | |
| 29540 | <1% | 35 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 881 | $1K |
| 84156 | <1% | 206 | $1K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 21 | $1K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 13 | $968.29 |
| 82785 | <1% | 74 | $967.45 | |
| 0074A | <1% | 26 | $931.43 | |
| 0151A | <1% | 24 | $922.74 | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 12 | $911.82 |
| 98967 | <1% | 266 | $883.68 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,204 | $876.70 |
| 84132 | <1% | 1,050 | $853.35 | |
| 80177 | <1% | 15 | $818.13 | |
| 92593 | <1% | 26 | $804.20 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 38 | $803.07 |
| 96161 | <1% | 27 | $792.28 | |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 16 | $776.00 |
| 84550 | <1% | 439 | $755.92 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 208 | $724.10 |
| 95908 | <1% | 12 | $707.35 | |
| 97161 | <1% | 12 | $684.37 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 40 | $679.04 |
| 99251 | <1% | 14 | $641.89 | |
| 73522 | <1% | 26 | $641.31 | |
| 99452 | <1% | 29 | $638.35 | |
| 83615 | <1% | 1,183 | $636.65 | |
| 96381 | <1% | 60 | $633.72 | |
| 86160 | <1% | 145 | $607.14 | |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | <1% | 67 | $605.98 |
| 0298T | <1% | 42 | $597.86 | |
| 99307 | <1% | 25 | $597.07 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 358 | $580.08 |
| 85379 | <1% | 461 | $578.64 | |
| 93016 | <1% | 38 | $576.50 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 126 | $557.32 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 31 | $548.97 |
| D0270 | <1% | 50 | $516.23 | |
| 72120 | <1% | 12 | $514.97 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 17 | $491.85 |
| 88346 | <1% | 13 | $489.06 | |
| 90732 | <1% | 69 | $488.26 | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 12 | $471.30 |
| 99241 | <1% | 15 | $463.67 | |
| 92540 | <1% | 13 | $453.37 | |
| 96136 | <1% | 15 | $450.27 | |
| 86140 | <1% | 174 | $434.97 | |
| 97542 | <1% | 12 | $404.28 | |
| 99497 | <1% | 18 | $389.37 | |
| 93018 | <1% | 38 | $386.85 | |
| 73070 | <1% | 36 | $345.44 | |
| 90461 | <1% | 16 | $343.25 | |
| 82040 | <1% | 40 | $338.68 | |
| 96367 | <1% | 31 | $303.38 | |
| 93320 | <1% | 13 | $298.45 | |
| 95251 | <1% | 14 | $254.54 | |
| 82784 | <1% | 86 | $250.38 | |
| 88311 | <1% | 14 | $245.02 | |
| 92555 | <1% | 12 | $231.96 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 12 | $226.78 |
| 82746 | <1% | 27 | $226.42 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 17 | $221.97 |
| 72020 | <1% | 34 | $217.25 | |
| 91303 | <1% | 85 | $215.93 | |
| 92650 | <1% | 29 | $210.36 | |
| 86256 | <1% | 130 | $199.16 | |
| 87272 | <1% | 21 | $179.55 | |
| 83718 | <1% | 36 | $176.45 | |
| 99358 | Prolong nursin fac eval 15m | <1% | 29 | $164.37 |
| 72190 | <1% | 14 | $152.97 | |
| 82610 | <1% | 12 | $128.40 | |
| 84520 | <1% | 167 | $126.88 | |
| 86235 | <1% | 81 | $122.66 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 76 | $122.08 |
| 90647 | <1% | 3,537 | $115.92 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 18 | $114.28 |
| 84702 | <1% | 14 | $109.56 | |
| G2063 | Qualified nonphysician healthcare professional online assessment and management service, for an established patient, for up to seven days, cumulative time during the 7 days; 21 or more minutes | <1% | 16 | $105.48 |
| 99177 | <1% | 26 | $99.19 | |
| 82465 | <1% | 12 | $94.87 | |
| 93922 | <1% | 12 | $87.74 | |
| 82550 | <1% | 60 | $83.22 | |
| 80081 | <1% | 14 | $83.11 | |
| G2062 | Qualified nonphysician healthcare professional online assessment and management service, for an established patient, for up to seven days, cumulative time during the 7 days; 11-20 minutes | <1% | 15 | $80.80 |
| H0048 | Alcohol and/or other drug testing: collection and handling only, specimens other than blood | <1% | 218 | $79.20 |
| 83789 | <1% | 187 | $77.13 | |
| 98966 | <1% | 197 | $71.25 | |
| 93325 | <1% | 17 | $63.26 | |
| 99422 | <1% | 86 | $62.85 | |
| 82024 | <1% | 18 | $61.79 | |
| 87109 | <1% | 62 | $61.25 | |
| 98962 | <1% | 31 | $59.15 | |
| 90681 | <1% | 445 | $40.26 | |
| 82248 | <1% | 26 | $39.69 | |
| 83516 | <1% | 46 | $27.98 | |
| 90611 | <1% | 163 | $19.73 | |
| 84295 | <1% | 19 | $17.32 | |
| 86039 | <1% | 24 | $13.54 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 23 | $10.12 |
| 90713 | <1% | 15 | $9.81 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 424 | $2.97 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 132 | $2.42 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 19 | $1.89 |
| 90685 | <1% | 134 | $0.01 | |
| T1001 | Nursing assessment / evaluation | 0% | 46 | $0.00 |
| 86325 | 0% | 14 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 316 | $0.00 |
| 90633 | 0% | 599 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 351 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 17 | $0.00 |
| 84630 | 0% | 19 | $0.00 | |
| 86200 | 0% | 30 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 82 | $0.00 |
| 90707 | 0% | 56 | $0.00 | |
| 85045 | 0% | 18 | $0.00 | |
| 86431 | 0% | 32 | $0.00 | |
| 82247 | 0% | 15 | $0.00 | |
| 87040 | 0% | 37 | $0.00 | |
| 90680 | 0% | 1,444 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 138 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 109 | $0.00 |
| 87430 | 0% | 494 | $0.00 | |
| 91318 | 0% | 180 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 26 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 15 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 50 | $0.00 |
| 90688 | 0% | 22 | $0.00 | |
| D1353 | 0% | 134 | $0.00 | |
| 76519 | 0% | 57 | $0.00 | |
| 82525 | 0% | 20 | $0.00 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 0% | 22 | $0.00 |
| 91319 | 0% | 52 | $0.00 | |
| 90899 | 0% | 18 | $0.00 | |
| D3120 | 0% | 21 | $0.00 | |
| 90660 | 0% | 38 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 27 | $0.00 |
| 90716 | 0% | 24 | $0.00 | |
| 83088 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, LISA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Hennepin Healthcare System, INC | Minneapolis, MN | $23.17M |
| Hennepin Healthcare System, INC | Minneapolis, MN | $12.40M |
| Hennepin Healthcare System, INC | Minneapolis, MN | $638K |
| Hennepin Healthcare System INC | Minneapolis, MN | $294K |
| Beyond Wellness PLLC | Boise, ID | $234K |
| Hennepin Healthcare System INC | Minneapolis, MN | $20K |
| Hennepin Healthcare System, INC | Minneapolis, MN | $958.39 |
| Ets Consulting LLC | Mountlake Terrace, WA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.